计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C167028-5mg |
5mg |
现货 ![]() |
| |
| C167028-10mg |
10mg |
现货 ![]() |
| |
| C167028-25mg |
25mg |
现货 ![]() |
| |
| C167028-50mg |
50mg |
现货 ![]() |
| |
| C167028-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | CP 101606 | MLS006010672 | 1-[(S)-2-(S)-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl-ethyl]-4-phenyl-piperidin-4-ol | BCP13195 | CP101606 | AKOS015959795 | Traxoprodil [INN] | DTXSID90158605 | TRAXOPRODIL [WHO-DD] | 134234-12-1 (free base) | Benzophenone,4'-bis( |
|---|---|
| 规格或纯度 | Moligand™, ≥98%(HPLC) |
| 英文名称 | CP-101,606 |
| 生化机理 | Traxoprodil (CP-101,606) is a potent noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, selective for the NR2B subunit. It has been shown to be neuroprotective in animal models of brain injury and stroke. CP-101,606 (Traxoprodil) plays a role in inhibiting glutamate-induced death in rats. It may exhibit therapeutic effects against human ischemia and neurodegenerative disorders. Traxoprodil is metabolized by cytochrome P450 (CYP) 2D6. |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 拮抗剂 |
| 作用机制 | 谷氨酸 NMDA 受体;GRIN1/GRIN2B 拮抗剂 |
| 产品介绍 |
CP-101,606 (Traxoprodil) is a substituted 4-phenylpiperidine and is localized in the fore brain neurons. CP-101,606 has been used as a N-methyl-D-aspartate (NMDA) receptor antagonist to study its role in recovery of spinal cord injuries. |
| 纯度 | ≥98%(HPLC) |
| ALogP | 2.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504757876 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol |
| INCHI | 1S/C20H25NO3/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17/h2-10,15,19,22-24H,11-14H2,1H3/t15-,19+/m0/s1 |
| InChi Key | QEMSVZNTSXPFJA-HNAYVOBHSA-N |
| Smiles | CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O |
| Isomeric SMILES | C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O |
| 分子量 | 327.42 |
| Reaxy-Rn | 13582904 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=13582904&ln= |
| 溶解性 | 二甲基亚砜:≥35毫克/毫升 |
|---|---|
| 分子量 | 327.400 g/mol |
| XLogP3 | 2.300 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 327.183 Da |
| 单同位素质量Monoisotopic Mass | 327.183 Da |
| 拓扑极表面积Topological Polar Surface Area | 63.900 Ų |
| 重原子数Heavy Atom Count | 24 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 380.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS06, GHS07, GHS09 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H301: 吞咽会中毒 H319: 引起严重眼睛刺激 H400: 对水生生物有剧毒 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P391: 收集溢出物 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P337+P317: 如果眼睛刺激持续:寻求医疗帮助。 |
| WGK Germany | 3 |